•Job Ref: MI/17/56
•Commencement of post: January 2018
•Duration of post: 3 years (in first instance)
A 3-year position is available for a highly motivated postdoctoral scientist in the laboratory of Professor Georges Lacaud to investigate the roles of the transcription factor RUNX1 and/or the epigenetic factor MOZ in normal haematopoiesis and leukaemia. The successful applicant will use different mouse models already available in the laboratory to identify genes and pathways regulated by these two transcriptional regulators either in normal or malignant haematopoiesis. Their relevance will be evaluated using state-of-the-art mouse models, CRISPR genome editing, ES cell and primary human leukaemia cell cultures. The ultimate goal of this work is to identify candidate therapeutic targets for potential drug development.
The successful applicant should have a PhD in molecular or cellular biology. A background in haematopoiesis or leukaemia is desirable but not required.
Informal enquiries should be directed to Georges Lacaud (
[email protected]).
The Cancer Research UK Manchester Institute (
www.cruk.manchester.ac.uk), an Institute of The University of Manchester (
www.manchester.ac.uk), is a world-leading centre for excellence in cancer research. The Institute is core funded by Cancer Research UK (
www.cancerresearchuk.org), the largest independent cancer research organisation in the world. We are currently situated at the internationally-renowned life sciences campus at Alderley Park in Cheshire, England, 15 miles from Manchester, a vibrant and dynamic city surrounded by beautiful countryside. We are partnered with The Christie NHS Foundation Trust (adjacent to the CRUK Manchester Institute, Paterson Building) in South Manchester (
www.christie.nhs.uk), one of the largest cancer treatment centres in Europe. These factors combine to provide an exceptional environment in which to pursue basic, translational and clinical research programmes.
Our aim is to understand the fundamental basis of cancer and apply that knowledge to developing new treatment strategies for cancer patients. Our advanced research programmes span a spectrum of cancer research, from the molecular and cellular basis of cancer through to drug discovery, translational research and clinical trials.
The Institute has outstanding laboratory facilities and exceptional core services, including next generation sequencing, microarrays, confocal microscopy, bioinformatics, histology and mass-spectrometry.
To apply for this position please visit our website:
www.cruk.manchester.ac.uk For applicants who are unable to download this information from our website, please contact HR department on 0161 306 0840, email:
[email protected] to have this information sent by post.
Closing date: 25 September 2017.
